Search

Displaying results 2081 - 2090 of 4301 in total
  1. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.

  2. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    of protein by the Krebs-Hanseleit cycle in the liver [L2033]. … It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis

  3. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.

  4. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...

  5. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

  6. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  7. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood

  8. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane has poor oral bioavailability, and thus must be administered fortnightly (bi-weekly) by intramuscular injection.

  9. Drug

    Polyethylene glycol

    go.drugbank.com/drugs/DB09287
    ApprovedInvestigationalVet approved

    Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. … [A190975] Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules.

  10. Drug

    Boric acid

    go.drugbank.com/drugs/DB11326
    ApprovedInvestigational

    Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and